U.S. Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025

Description

U.S. Nuclear Medicine Market was valued at USD 7.8 billion in 2024 and is estimated to grow at a CAGR of 14.4% to reach USD 30.7 billion by 2034.

The robust growth is fueled by the rise of radiopharmaceutical innovations, increased incidence of chronic diseases, expanding use of personalized treatments, and supportive reimbursement frameworks. Nuclear medicine, a highly specialized area of medical imaging and therapy, utilizes radiopharmaceuticals to both diagnose and treat medical conditions. Unlike traditional imaging methods, nuclear techniques offer deeper molecular and functional insight into tissues and organs. As the healthcare industry moves toward precision care, nuclear imaging is gaining prominence for its ability to deliver accurate diagnostics and targeted therapies. The sector is also being shaped by technological breakthroughs, the surge of oncology theranostics, rising investment in drug development, and an expanding network of diagnostic facilities. Theranostics is accelerating adoption in cancer care by combining imaging and therapeutic solutions into one approach. This enables real-time tracking of targeted radiopharmaceuticals, improving therapeutic precision and minimizing adverse effects, especially in oncology cases.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$7.8 Billion
Forecast Value	$30.7 Billion
CAGR	14.4%

The diagnostics segment held a 66.5% share in 2024, due to growing demand for early-stage disease detection. The rising burden of cancer, heart disease, and neurological disorders is prompting widespread use of imaging platforms like PET and SPECT. These technologies provide accurate and early detection of illness, allowing for more effective and personalized treatment plans. Their ability to identify disease before structural changes occur is driving broader clinical acceptance.

The cardiology segment is projected to register a CAGR of 14.6% through 2034. This growth is backed by the rising number of patients with cardiovascular conditions and the need for accurate diagnostic procedures. Nuclear imaging modalities are proving critical in evaluating cardiac health, guiding physicians with detailed functional imaging that supports timely interventions.

South Atlantic Nuclear Medicine Market held a 19.4% share in 2024. Increased investment in healthcare infrastructure in this zone, especially in states such as Georgia and Florida, has expanded patient access to nuclear diagnostics. Improvements in radiopharmaceutical efficacy and imaging hardware have also contributed to wider adoption across both hospitals and outpatient clinics in this area.

Key players shaping the U.S. Nuclear Medicine Market include Sirtex, GE Healthcare, Theragenics, Cardinal Health, RadioMedix, Lantheus, Curium Pharma, Novartis, Sun Pharma, Siemens Healthineers, Jubilant Pharma, RLS Radiopharmacies, Boston Scientific, Bracco, and Actinium Pharmaceuticals. To maintain a competitive edge in the U.S. Nuclear Medicine companies are prioritizing innovation in radiopharmaceutical development and strengthening their production and distribution networks. Many are investing in theranostic capabilities, targeting cancer and rare diseases with dual-function agents that offer both diagnosis and treatment. Strategic mergers, partnerships with diagnostic centers, and collaborations with academic institutions are common to accelerate clinical research and expand product pipelines. Additionally, manufacturers are enhancing supply chain efficiency by setting up regional radiopharmacies for faster delivery. Companies are also focused on securing FDA approvals for new compounds and expanding indications of existing ones, ensuring strong market penetration. Integration of AI with nuclear imaging platforms is another tactic being explored to improve diagnostic accuracy and clinical outcomes.

Product Code: 11978

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Data mining sources
1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
1.5 Primary research and validation
- 1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis
2.2 Key market trends
- 2.2.1 Zonal trends
- 2.2.2 Product trends
- 2.2.3 Application trends
- 2.2.4 End use trends
2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cancer and cardiovascular diseases
  - 3.2.1.2 Increasing demand for early and accurate disease diagnosis
  - 3.2.1.3 Technological advancements in imaging systems (PET, SPECT)
  - 3.2.1.4 Expanding applications of radiopharmaceuticals in therapy
  - 3.2.1.5 Supportive government initiatives and funding
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of nuclear medicine procedures and equipment
  - 3.2.2.2 Short half-life and limited availability of radioisotopes
- 3.2.3 Market opportunities
  - 3.2.3.1 Growing adoption of targeted radionuclide therapies
  - 3.2.3.2 Advancements in hybrid imaging technologies
  - 3.2.3.3 Increasing research in novel radiopharmaceuticals
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technology landscape
- 3.6.1 Current technological trends
- 3.6.2 Emerging technologies
3.7 Pipeline analysis
3.8 Investment landscape
3.9 Future market trends
3.10 Value chain analysis
3.11 Porter's analysis
3.12 PESTEL analysis
3.13 Gap analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Competitive analysis of major market players
4.6 Key developments
- 4.6.1 Mergers & acquisitions
- 4.6.2 Partnerships & collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Diagnostics
- 5.2.1 Single photon emission computed tomography (SPECT) isotopes
  - 5.2.1.1 TC-99m
  - 5.2.1.2 I-123
  - 5.2.1.3 GA-67
  - 5.2.1.4 TL-201
  - 5.2.1.5 Other SPECT isotopes
- 5.2.2 Positron emission tomography (PET) isotopes
  - 5.2.2.1 F-18
  - 5.2.2.2 RB-82
  - 5.2.2.3 Other PET isotopes
5.3 Therapeutics
- 5.3.1 Beta emitters
  - 5.3.1.1 I-131
  - 5.3.1.2 Lu-177
  - 5.3.1.3 Y-90
  - 5.3.1.4 SM-153
  - 5.3.1.5 Re-186
  - 5.3.1.6 Other beta emitters
- 5.3.2 Brachytherapy isotopes
  - 5.3.2.1 Iridium-192
  - 5.3.2.2 Iodine-125
  - 5.3.2.3 Cesium-131
  - 5.3.2.4 Palladium-103
  - 5.3.2.5 Other brachytherapy isotopes
- 5.3.3 Alpha emitters
  - 5.3.3.1 RA-223
  - 5.3.3.2 Other alpha emitters

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Neurology
6.3 Cardiology
6.4 Oncology
6.5 Thyroid
6.6 Pulmonary
6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic centers
7.4 Research institutes
7.5 Other End use

Chapter 8 Market Estimates and Forecast, By Zone, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 East North Central
8.3 West South Central
8.4 South Atlantic
8.5 Northeast
8.6 East South Central
8.7 West North Central
8.8 Pacific Central
8.9 Mountain States

Chapter 9 Company Profiles

9.1 Actinium Pharmaceuticals
9.2 Boston Scientific
9.3 Bracco
9.4 Cardinal Health
9.5 Curium Pharma
9.6 GE Healthcare
9.7 Jubilant Pharma
9.8 Lantheus
9.9 Novartis
9.10 RadioMedix
9.11 RLS Radiopharmacies
9.12 Siemens Healthineers
9.13 Sirtex
9.14 Sun Pharma
9.15 Theragenics

U.S. Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034